Medivation, Inc. (MDVN) Files Form 4 Insider Selling : Andrew Kenneth William Powell Sells 2,578 Shares

Medivation, Inc. (MDVN): Andrew Kenneth William Powell , SVP, General Counsel & Crp Sec of Medivation, Inc. sold 2,578 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $60.42 per share for a total value of $155,762.77 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 9, 2016, Rick Bierly (CFO (former) sold 10,340 shares at $59.98 per share price.On Mar 16, 2016, Dawn Svoronos (director) sold 6,000 shares at $38.90 per share price.Also, On Mar 7, 2016, David Hung (President and CEO) sold 5,085 shares at $41.10 per share price.On Mar 7, 2016, Mohammad Hirmand (Interim Chief Medical Officer) sold 1,525 shares at $41.10 per share price.

Shares of Medivation Inc (MDVN) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.17 points or -0.28% at $60.8 with 16,82,864 shares getting traded. Post opening the session at $60.6, the shares hit an intraday low of $60.27 and an intraday high of $61.075 and the price vacillated in this range throughout the day. The company has a market cap of $10,009 M and the number of outstanding shares has been calculated to be 16,46,24,780 shares. The 52-week high of Medivation Inc is $62.94 and the 52-week low is $26.41.

Medivation Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.Medivation Inc is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 70 from a previous price target of $48 .The Rating was issued on May 6, 2016.Medivation Inc is Upgraded by Citigroup to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 6, 2016.Medivation Inc is Reiterated by Maxim Group to Buy and the brokerage firm has raised the Price Target to $ 76 from a previous price target of $47 .The Rating was issued on May 5, 2016.Medivation Inc is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 66 from a previous price target of $52 .The Rating was issued on May 2, 2016.Medivation Inc is Reiterated by Jefferies to Hold and the brokerage firm has raised the Price Target to $ 52 from a previous price target of $39 .The Rating was issued on May 2, 2016.

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Leave a Reply

Medivation Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Medivation Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.